N/A N=191 Using Digital Media Advertising to Reduce the Duration of Untreated Psychosis
Schizophrenia · First Episode Psychosis
Primary: Reducing the Duration of Untreated Psychosis — 5.32; 5.38 Days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Melanoma · Metastatic Melanoma · Mucosal Melanoma
Primary: Number of Participants With Treatment-related Adverse Events Per Study Arm — 0; 0; 0; 0 Participants
Phase 4 N=60 Subacromial Injection of Epinephrine Improves Visualization in Shoulder Arthroscopy
Shoulder Arthroscopy
Primary: Surgeon-rated Visual Clarity as Assessed by the Visual Analog Scale — 8.3; 7.5 score on a scale
Phase 2 N=1,435 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Prostate Cancer · Prostate Adenocarcinoma · Prostate Cancer Metastatic
Primary: Positive Predictive Value (PPV) of 68Ga PSMA PET/CT for Detecting Prostate Cancer on a Per-patient Basis Confirmed by Histopathology. — 87.3 percentage of times value is…
Phase 2 N=5 Clostridium Histolyticum Collagenase Injection for Urethral Disease
Urethral Stricture
Primary: Number of Subjects With Complication After Treatment — 0 Participants
Phase 1 N=10 Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
Cocaine Dependence · Cocaine Addiction · Cocaine Abuse
Primary: Number of Participants With Severe Adverse Events (AEs) — 0; 0; 0; 0 Participants
Phase 2 N=78 Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material
Esophageal Adenocarcinoma
Primary: Number of Participants With Anastomotic Leak. — 10; 68 Participants
Phase 3 N=127 Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
ADHD
Primary: Lean Squares Mean (± Standard Error) of Math Test Score Over All Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the…
N/A N=164 ACCESS: AI for pediatriC diabetiC Eye examS Study
Type 1 Diabetes · Type 2 Diabetes
Primary: Number of Participants Who Get Screened With a Diabetic Eye Exam — 18; 81 Participants
Phase 3 N=52 Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
Alagille Syndrome
Primary: Change From Baseline in Scratching Score — -1.69; -0.8 score on a scale — p=0.0012
Phase 2 N=144 A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Moderate to Severe Ulcerative Colitis
Primary: Change From Baseline for Adapted Mayo Score: 0.2 mg Versus Placebo — -2.60; -1.95 score on a scale
Phase 4 N=20 Intercostal Nerve Cryoablation for Postoperative Pain Management
Pain, Postoperative
Primary: Score on Numeric Pain Scale (NPS) — 1.5; 3 score on a scale
Phase 3 N=89 Efficacy and Safety of Sirolimus in LAM
Lymphangioleiomyomatosis
Primary: Changes in Forced Expiratory Volume in One-second (FEV1) Slope in Milliliters Per Month — 1; -12 milliliters per month — p=<0.001
Phase 4 N=26 Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE
Hepatocellular Carcinoma
Primary: Residual Disease on CEUS Imaging. — 19 lesions
Phase 3 N=148 A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
Mild Cognitive Impairment (MCI) · Alzheimer Disease
Primary: Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus…